When to lower triglycerides?

Current Opinion in Lipidology
Om P Ganda

Abstract

Substantial risk of ASCVD events persists despite intensive statin therapy and other agents to lower LDL-C. The optimal way to address other elements of dyslipidemia, such as triglyceride-rich particles (TRL) and when to treat has remained unclear. Several lines of evidence indicate that TRL are associated with atherogenesis, partly because of associated factors, such as cholesterol-enriched remnant particles, high LDL particle number, high apo-B, high apo-CIII, and others. High triglyceride is increasingly prevalent because of worsening of lifestyle factors, obesity, and diabetes. Trials with fibrates, and niacin to reduce residual dyslipidemia have not provided evidence of benefits after statin therapy, thus far. A recent trial with an omega 3 fatty acid (OM3FA), icosapent-ethyl (IPE), provided evidence for a 25% reduction in ASCVD events in statin-treated high-risk population. These results were unexplained by triglyceride reduction alone, and are likely related to unique biologic effects of IPE on atherosclerosis. Finally, in patients with very high triglycerides, lifestyle measures and several triglyceride-lowering agents are indicated, often in combination, to prevent episodes of pancreatitis. A novel Apo C-III inhibitor ...Continue Reading

References

Apr 3, 2007·Lancet·Mitsuhiro YokoyamaUNKNOWN Japan EPA lipid intervention study (JELIS) Investigators
Jan 15, 2008·Lancet·UNKNOWN Cholesterol Treatment Trialists' (CTT) CollaboratorsC Baigent
Feb 19, 2008·Journal of the American College of Cardiology·Michael MillerUNKNOWN PROVE IT-TIMI 22 Investigators
Mar 17, 2010·The New England Journal of Medicine·Henry N GinsbergRobert P Byington
Jul 12, 2014·The New England Journal of Medicine·UNKNOWN HPS2-THRIVE Collaborative GroupJane Armitage
Aug 19, 2014·Lancet·Børge G Nordestgaard, Anette Varbo
Jan 13, 2015·Arteriosclerosis, Thrombosis, and Vascular Biology·Sumeet A Khetarpal, Daniel J Rader
Mar 4, 2015·Nature Reviews. Endocrinology·Amanda J Brahm, Robert A Hegele
Jul 30, 2015·The New England Journal of Medicine·Daniel GaudetJohn J P Kastelein
Feb 20, 2016·Circulation Research·Kiran Musunuru, Sekar Kathiresan
Mar 8, 2017·JAMA : the Journal of the American Medical Association·Amit V KheraUNKNOWN Myocardial Infarction Genetics Consortium, DiscovEHR Study Group, CARDIoGRAM Exome Consortium, and Global Lipids Genetics Co
Mar 17, 2017·Nature Reviews. Cardiology·Željko Reiner
May 26, 2017·The New England Journal of Medicine·Mark J GrahamSotirios Tsimikas
May 26, 2017·The New England Journal of Medicine·Frederick E DeweyAris Baras
Mar 2, 2018·The Journal of Clinical Investigation·Samir SofticC Ronald Kahn
Mar 9, 2018·Endocrine Reviews·George A BrayThomas H Inge
Mar 20, 2018·Journal of Clinical Lipidology·David S Olshan, Daniel J Rader
Jun 25, 2018·Journal of the American College of Cardiology·Om P GandaWilliam E Boden
Oct 17, 2018·Current Diabetes Reports·Om Ganda
Nov 13, 2018·The New England Journal of Medicine·Deepak L BhattUNKNOWN REDUCE-IT Investigators
Nov 13, 2018·The New England Journal of Medicine·JoAnn E MansonUNKNOWN VITAL Research Group
Dec 31, 2018·Journal of Clinical Lipidology·Wenjun FanNathan D Wong
Jan 30, 2019·JAMA : the Journal of the American Medical Association·Brian A FerenceAlberico L Catapano
Mar 14, 2019·The New England Journal of Medicine·Kausik K RayUNKNOWN CLEAR Harmony Trial
Mar 23, 2019·Journal of the American College of Cardiology·Deepak L BhattUNKNOWN REDUCE-IT Investigators
Apr 30, 2019·Annals of Internal Medicine·Alan Chait, Robert H Eckel
Aug 8, 2019·The New England Journal of Medicine·Joseph L WitztumEric Bruckert
Aug 20, 2019·Circulation·Ann C Skulas-RayUNKNOWN American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometa
Oct 9, 2019·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·Karl Boden

❮ Previous
Next ❯

Citations

Jul 16, 2021·Expert Review of Cardiovascular Therapy·Julieta Lazarte, Robert A Hegele
Oct 23, 2021·Endocrine Reviews·Amanda J Berberich, Robert A Hegele
Dec 5, 2020·Journal of the American College of Cardiology·John R BurnettRobert A Hegele

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.